7 results on '"Jamison, Allison"'
Number of results to display per page
Search Results
2. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry
- Author
-
Cuchel, Marina, Lee, Paul C., Hudgins, Lisa C., Duell, P. Barton, Ahmad, Zahid, Baum, Seth J., Linton, MacRae F., de Ferranti, Sarah D., Ballantyne, Christie M., Larry, John A., Hemphill, Linda C., Kindt, Iris, Gidding, Samuel S., Martin, Seth S., Moriarty, Patrick M., Thompson, Paul P., Underberg, James A., Guyton, John R., Andersen, Rolf L., Whellan, David J., Benuck, Irwin, Kane, John P., Myers, Kelly, Howard, William, Staszak, David, Jamison, Allison, Card, Mary C., Bourbon, Mafalda, Chora, Joana R., Rader, Daniel J., Knowles, Joshua W., Wilemon, Katherine, McGowan, Mary P., Cuchel, Marina, Lee, Paul C., Hudgins, Lisa C., Duell, P. Barton, Ahmad, Zahid, Baum, Seth J., Linton, MacRae F., de Ferranti, Sarah D., Ballantyne, Christie M., Larry, John A., Hemphill, Linda C., Kindt, Iris, Gidding, Samuel S., Martin, Seth S., Moriarty, Patrick M., Thompson, Paul P., Underberg, James A., Guyton, John R., Andersen, Rolf L., Whellan, David J., Benuck, Irwin, Kane, John P., Myers, Kelly, Howard, William, Staszak, David, Jamison, Allison, Card, Mary C., Bourbon, Mafalda, Chora, Joana R., Rader, Daniel J., Knowles, Joshua W., Wilemon, Katherine, and McGowan, Mary P.
- Abstract
Background Homozygous familial hypercholesterolemia (HoFH) is a rare, treatment‐resistant disorder characterized by early‐onset atherosclerotic and aortic valvular cardiovascular disease if left untreated. Contemporary information on HoFH in the United States is lacking, and the extent of underdiagnosis and undertreatment is uncertain. Methods and Results Data were analyzed from 67 children and adults with clinically diagnosed HoFH from the CASCADE (Cascade Screening for Awareness and Detection) FH Registry. Genetic diagnosis was confirmed in 43 patients. We used the clinical characteristics of genetically confirmed patients with HoFH to query the Family Heart Database, a US anonymized payer health database, to estimate the number of patients with similar lipid profiles in a “real‐world” setting. Untreated low‐density lipoprotein cholesterol levels were lower in adults than children (533 versus 776 mg/dL; P=0.001). At enrollment, atherosclerotic cardiovascular disease and supravalvular and aortic valve stenosis were present in 78.4% and 43.8% and 25.5% and 18.8% of adults and children, respectively. At most recent follow‐up, despite multiple lipid‐lowering treatment, low‐density lipoprotein cholesterol goals were achieved in only a minority of adults and children. Query of the Family Heart Database identified 277 individuals with profiles similar to patients with genetically confirmed HoFH. Advanced lipid‐lowering treatments were prescribed for 18%; 40% were on no lipid‐lowering treatment; atherosclerotic cardiovascular disease was reported in 20%; familial hypercholesterolemia diagnosis was uncommon. Conclusions Only patients with the most severe HoFH phenotypes are diagnosed early. HoFH remains challenging to treat. Results from the Family Heart Database indicate HoFH is systemically underdiagnosed and undertreated. Earlier screening, aggressive lipid‐lowering treatments, and guideline implementation are required to reduce disease burden in HoFH.
- Published
- 2023
3. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia:A Global Call to Action
- Author
-
Wilemon, Katherine A., Patel, Jasmine, Aguilar-Salinas, Carlos, Ahmed, Catherine D., Alkhnifsawi, Mutaz, Almahmeed, Wael, Alonso, Rodrigo, Al-Rasadi, Khalid, Badimon, Lina, Bernal, Luz M., Bogsrud, Martin P., Braun, Lynne T., Brunham, Liam, Catapano, Alberico L., Čillíková, Kristyna, Corral, Pablo, Cuevas, Regina, Defesche, Joep C., Descamps, Olivier S., De Ferranti, Sarah, Eiselé, Jean Luc, Elikir, Gerardo, Folco, Emanuela, Freiberger, Tomas, Fuggetta, Francesco, Gaspar, Isabel M., Gesztes, Ákos G., Grošelj, Urh, Hamilton-Craig, Ian, Hanauer-Mader, Gabriele, Harada-Shiba, Mariko, Hastings, Gloria, Hovingh, G. Kees, Izar, Maria C., Jamison, Allison, Karlsson, Gunnar N., Kayikçioǧlu, Meral, Koob, Sue, Koseki, Masahiro, Lane, Stacey, Lima-Martinez, Marcos M., López, Greizy, Martinez, Tania L., Marais, David, Marion, Letrillart, Mata, Pedro, Maurina, Inese, Maxwell, Diana, Mehta, Roopa, Nordestgaard, Børge G., Wilemon, Katherine A., Patel, Jasmine, Aguilar-Salinas, Carlos, Ahmed, Catherine D., Alkhnifsawi, Mutaz, Almahmeed, Wael, Alonso, Rodrigo, Al-Rasadi, Khalid, Badimon, Lina, Bernal, Luz M., Bogsrud, Martin P., Braun, Lynne T., Brunham, Liam, Catapano, Alberico L., Čillíková, Kristyna, Corral, Pablo, Cuevas, Regina, Defesche, Joep C., Descamps, Olivier S., De Ferranti, Sarah, Eiselé, Jean Luc, Elikir, Gerardo, Folco, Emanuela, Freiberger, Tomas, Fuggetta, Francesco, Gaspar, Isabel M., Gesztes, Ákos G., Grošelj, Urh, Hamilton-Craig, Ian, Hanauer-Mader, Gabriele, Harada-Shiba, Mariko, Hastings, Gloria, Hovingh, G. Kees, Izar, Maria C., Jamison, Allison, Karlsson, Gunnar N., Kayikçioǧlu, Meral, Koob, Sue, Koseki, Masahiro, Lane, Stacey, Lima-Martinez, Marcos M., López, Greizy, Martinez, Tania L., Marais, David, Marion, Letrillart, Mata, Pedro, Maurina, Inese, Maxwell, Diana, Mehta, Roopa, and Nordestgaard, Børge G.
- Abstract
Importance: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. Observations: In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing
- Published
- 2020
4. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action
- Author
-
Wilemon, Katherine A., Patel, Jasmine, Aguilar-Salinas, Carlos, Ahmed, Catherine D., Alkhnifsawi, Mutaz, Almahmeed, Wael, Alonso, Rodrigo, Al-Rasadi, Khalid, Badimon, Lina, Bernal, Luz M., Bogsrud, Martin P., Braun, Lynne T., Brunham, Liam, Catapano, Alberico L., Cillíková, Kristyna, Corral, Pablo, Cuevas, Regina, Defesche, Joep C., Descamps, Olivier S., de Ferranti, Sarah, Eiselé, Jean-Luc, Elikir, Gerardo, Folco, Emanuela, Freiberger, Tomas, Fuggetta, Francesco, Gaspar, Isabel M., Gesztes, Ákos G., Grošelj, Urh, Hamilton-Craig, Ian, Hanauer-Mader, Gabriele, Harada-Shiba, Mariko, Hastings, Gloria, Hovingh, G. Kees, Izar, Maria C., Jamison, Allison, Karlsson, Gunnar N., Kayikçioglu, Meral, Koob, Sue, Koseki, Masahiro, Lane, Stacey, Lima-Martinez, Marcos M., López, Greizy, Martinez, Tania L., Marais, David, Marion, Letrillart, Mata, Pedro, Maurina, Inese, Maxwell, Diana, Mehta, Roopa, Mensah, George A., Miserez, André R., Neely, Dermot, Nicholls, Stephen J., Nohara, Atsushi, Nordestgaard, Børge G., Ose, Leiv, Pallidis, Athanasios, Pang, Jing, Payne, Jules, Peterson, Amy L., Popescu, Monica P., Puri, Raman, Ray, Kausik K., Reda, Ashraf, Sampietro, Tiziana, Santos, Raul D., Schalkers, Inge, Schreier, Laura, Shapiro, Michael D., Sijbrands, Eric, Soffer, Daniel, Stefanutti, Claudia, Stoll, Mario, Sy, Rody G., Tamayo, Martha L., Tilney, Myra K., Tokgözoglu, Lale, Tomlinson, Brian, Vallejo-Vaz, Antonio J., Vazquez-Cárdenas, Alejandra, de Luca, Patrícia Vieira, Wald, David S., Watts, Gerald F., Wenger, Nanette K., Wolf, Michaela, Wood, David, Zegerius, Aram, Gaziano, Thomas A., and Gidding, Samuel S.
- Abstract
IMPORTANCE: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. OBSERVATIONS: In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing country-specific and international FH scientific statements and guidelines, country-specific and international FH registries, and known FH advocacy organizations around the world were created. CONCLUSIONS AND RELEVANCE: By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countries have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene associated with FH and, likely, all those with severe hypercholesterolemia as well.
- Published
- 2020
- Full Text
- View/download PDF
5. Patient counseling practices in U.S. pharmacies: Effects of having pharmacists hand the medication to the patient and state regulations on pharmacist counseling
- Author
-
Kimberlin, Carole L., primary, Jamison, Allison Newland, additional, Linden, Stephan, additional, and Winterstein, Almut G., additional
- Published
- 2011
- Full Text
- View/download PDF
6. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia A Global Call to Action
- Author
-
Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana. Grupo de investigación Instituto de Genética Humana, López Leal, Greizy, Tamayo, Martha Lucia, Wilemon, Katherine A., Patel, Jasmine, Aguilar-Salinas, Carlos, Ahmed, Catherine D., Alkhnifsawi, Mutaz, Almahmeed, Wael, Alonso, Rodrigo, Al-Rasadi, Khalid, Badimon, Lina, Bernal, Luz M., Bogsrud, Martin P., Braun, Lynne T., Brunham, Liam, Catapano, Alberico L., Čillíková, Kristyna, Corral, Pablo, Cuevas, Regina, Defesche, Joep C., Descamps, Olivier S., de Ferranti, Sarah, Eiselé, Jean-Luc, Elikir, Gerardo, Folco, Emanuela, Freiberger, Tomas, Fuggetta, Francesco, Gaspar, Isabel M., Gesztes, Ákos G., Grošelj, Urh, Hamilton-Craig, Ian, Hanauer-Mader, Gabriele, Harada-Shiba, Mariko, Hastings, Gloria, Hovingh, G. Kees, Izar, Maria C., Jamison, Allison, Kayikçioğlu, Meral, Koob, Sue, Koseki, Masahiro, Lane, Stacey, Lima-Martinez, Marcos M., Martinez, Tania L., Marais, David, Marion, Letrillart, Mata, Pedro, Maurina, Inese, Maxwell, Diana, Mehta, Roopa, Mensah, George A., Miserez, André R., Neely, Dermot, Nicholls, Stephen J., Nohara, Atsushi, Nordestgaard, Børge G., Ose, Leiv, Pallidis, Athanasios, Pang, Jing, Payne, Jules, Peterson, Amy L., Popescu, Monica P., Puri, Raman, Ray, Kausik K., Reda, Ashraf, Sampietro, Tiziana, Santos, Raul D., Schalkers, Inge, Schreier, Laura, Shapiro, Michael D., Sijbrands, Eric, Soffer, Daniel, Stefanutti, Claudia, Stoll, Mario, Sy, Rody G., Tilney, Myra K., Tokgözoğlu, Lale, Tomlinson, Brian, Vallejo-Vaz, Antonio J., Vazquez-Cárdenas, Alejandra, Vieira de Luca, Patrícia, Wald, David S., Watts, Gerald F., Wenger, Nanette K., Wolf, Michaela, Wood, David, Zegerius, Aram, Gaziano, Thomas A., Gidding, Samuel S., Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana. Grupo de investigación Instituto de Genética Humana, López Leal, Greizy, Tamayo, Martha Lucia, Wilemon, Katherine A., Patel, Jasmine, Aguilar-Salinas, Carlos, Ahmed, Catherine D., Alkhnifsawi, Mutaz, Almahmeed, Wael, Alonso, Rodrigo, Al-Rasadi, Khalid, Badimon, Lina, Bernal, Luz M., Bogsrud, Martin P., Braun, Lynne T., Brunham, Liam, Catapano, Alberico L., Čillíková, Kristyna, Corral, Pablo, Cuevas, Regina, Defesche, Joep C., Descamps, Olivier S., de Ferranti, Sarah, Eiselé, Jean-Luc, Elikir, Gerardo, Folco, Emanuela, Freiberger, Tomas, Fuggetta, Francesco, Gaspar, Isabel M., Gesztes, Ákos G., Grošelj, Urh, Hamilton-Craig, Ian, Hanauer-Mader, Gabriele, Harada-Shiba, Mariko, Hastings, Gloria, Hovingh, G. Kees, Izar, Maria C., Jamison, Allison, Kayikçioğlu, Meral, Koob, Sue, Koseki, Masahiro, Lane, Stacey, Lima-Martinez, Marcos M., Martinez, Tania L., Marais, David, Marion, Letrillart, Mata, Pedro, Maurina, Inese, Maxwell, Diana, Mehta, Roopa, Mensah, George A., Miserez, André R., Neely, Dermot, Nicholls, Stephen J., Nohara, Atsushi, Nordestgaard, Børge G., Ose, Leiv, Pallidis, Athanasios, Pang, Jing, Payne, Jules, Peterson, Amy L., Popescu, Monica P., Puri, Raman, Ray, Kausik K., Reda, Ashraf, Sampietro, Tiziana, Santos, Raul D., Schalkers, Inge, Schreier, Laura, Shapiro, Michael D., Sijbrands, Eric, Soffer, Daniel, Stefanutti, Claudia, Stoll, Mario, Sy, Rody G., Tilney, Myra K., Tokgözoğlu, Lale, Tomlinson, Brian, Vallejo-Vaz, Antonio J., Vazquez-Cárdenas, Alejandra, Vieira de Luca, Patrícia, Wald, David S., Watts, Gerald F., Wenger, Nanette K., Wolf, Michaela, Wood, David, Zegerius, Aram, Gaziano, Thomas A., and Gidding, Samuel S.
7. It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States.
- Author
-
Gidding SS, Ballantyne CM, Cuchel M, de Ferranti S, Hudgins L, Jamison A, McGowan MP, Peterson AL, Steiner RD, Uveges MK, and Wang Y
- Subjects
- Child, Humans, Cholesterol, LDL blood, Homozygote, Mass Screening methods, Neonatal Screening methods, United States epidemiology, Infant, Newborn, Hyperlipoproteinemia Type II diagnosis, Hyperlipoproteinemia Type II epidemiology, Hyperlipoproteinemia Type II genetics
- Abstract
Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately one in 300,000 people. The disorder is characterized by extremely high, life-threatening levels of low-density lipoprotein (LDL) cholesterol from birth, leading to significant premature cardiovascular morbidity and mortality, if left untreated. Homozygous familial hypercholesterolemia is severely underdiagnosed and undertreated in the United States (US), despite guidelines recommendations for universal pediatric lipid screening in children aged 9-11. Early diagnosis and adequate treatment are critical in averting premature cardiovascular disease in individuals affected by HoFH. Yet, an unacceptably high number of people living with HoFH remain undiagnosed, misdiagnosed, and/or receive a late diagnosis, often after a major cardiovascular event. The emergence of novel lipid-lowering therapies, along with the realization that diagnosis is too often delayed, have highlighted an urgency to implement policies that ensure timely detection of HoFH in the US. Evidence from around the world suggests that a combination of universal pediatric screening and cascade screening strategies constitutes an effective approach to identifying heterozygous familial hypercholesterolemia (HeFH). Nevertheless, HoFH and its complications manifest much earlier in life compared to HeFH. To date, little focus has been placed on the detection of HoFH in very young children and/or infants. The 2023 Updated European Atherosclerosis Society Consensus Statement on HoFH has recommended, for the first time, broadening pediatric guidelines to include lipid screening of newborn infants. Some unique aspects of HoFH need to be considered before implementing newborn screening. As such, insights from pilot studies conducted in Europe may provide some preliminary guidance. Our paper proposes a set of actionable measures that states can implement to reduce the burden of HoFH. It also outlines key research and policy gaps that need to be addressed in order to pave the way for universal newborn screening of HoFH in the US., Competing Interests: The authors have no competing interests to declare., (Copyright: © 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.